13Worth It for Whom? Access, Equity and the Global Picture
Every cost-utility verdict so far carries a hidden assumption: that the country paying can afford the threshold. Shift the willingness-to-pay ceiling from a rich economy to a poor one and the same implant, with the same clinical benefit, can move from clearly worth it to economically unjustifiable. This module follows the cost-effectiveness argument out of the high-income clinic and into the low- and middle-income world, takes India as a worked example, and closes the chapter on the equity question the numbers cannot settle alone.
TThe threshold is local: why the same QALY costs more to justify
WHO-CHOICE classifies an intervention as cost-effective when its cost per QALY falls below roughly 1 to 3 times a country's GDP per capita, so the willingness-to-pay ceiling is set by national wealth rather than by the implant itself. In a high-income setting adult unilateral cochlear implantation sits at a pooled weighted average of about $12,847 per QALY (range roughly $9,000 to $31,177), comfortably under thresholds of $20,000 to $50,000 per QALY. In a low-income country with GDP per capita near $1,500, the same 1-to-3x rule yields a willingness-to-pay ceiling of only about $1,500 to $4,500 per QALY, below the cost per QALY that looks obviously cost-effective in wealthy economies. The clinical benefit is unchanged across borders: profound adult deafness still carries a health-utility decrement of about -0.46, and an implant still returns roughly +0.26 QALYs; only the affordability verdict moves.[2009][1999][1996]
CThe affordability gap and India as a worked example
Total device-plus-surgery cost typically runs $25,000 to $100,000 USD, which can exceed 100 times annual per capita income in South Asian and sub-Saharan settings where GDP per capita is roughly $1,000 to $5,000. Procurement context drives a more-than-twofold price spread for identical technology: middle-income countries reach $15,000 to $40,000 through competitive procurement and local assembly, whereas sub-Saharan settings face over $50,000 from import tariffs and weak supply chains. India's Assistive Devices & Implants (ADIP) program and state-level schemes subsidise 50 to 100 percent of implant cost for eligible beneficiaries, partially closing the affordability gap rather than the device price itself. Subsidy does not equal access: persistent barriers include low awareness, implant centres concentrated in urban areas, and thin post-implant rehabilitation in rural regions, and rehabilitation is what converts a funded device into a clinical outcome.[2009][2022][2022]
TLevers that move the verdict in poorer economies
Because cost per QALY is net cost divided by net QALYs, the verdict in a low-threshold economy can be moved either by cutting device price or by capturing more of the benefit; both shift the ICER toward the local ceiling. Switching from a health-system to a societal perspective adds offsets such as avoided special-education cost; in children, mainstream placement rates rise to around 75 percent after 4 years of implant use versus near 0 percent without an implant, and educational savings of $30,000 to $200,000 per year strengthen the case. Children gain more economic headroom than adults: paediatric cost-utility scenarios span roughly $3,111 to $25,450 per QALY depending on age at implant and educational trajectory, with earlier implantation yielding the most favourable ratios. Bilateral implantation is the first benefit to fall away under a tight threshold: the second ear adds roughly $50,000 to over $150,000 per QALY, so resource-limited programmes rationally prioritise first-ear access over second-ear optimisation.[2000][2006][2002][2009]
CThe equity argument that closes the chapter
About 400 million people worldwide live with moderate-to-profound hearing loss, and more than 80 percent of them are in low- and middle-income countries, precisely where thresholds are lowest and access is thinnest. Fewer than 5 percent of potential candidates in these regions are implanted, so a clinically proven, cost-effective-where-affordable intervention leaves the bulk of its global disease burden and DALY impact unaddressed. A pure GDP-indexed threshold systematically values the same restored hearing less in a poor country than a rich one; the equity counter-argument is that the burden is concentrated exactly where the strict cost-per-QALY rule withholds the device. The practical resolution is not to abandon cost-utility but to attack its inputs: lower device prices, pooled procurement, financing mechanisms, and locally delivered rehabilitation, so that an intervention worth it in Baltimore can also be worth it in Bengaluru.[2021][2009][2022]
Why does the unilateral implant programme fail to clear the cost-effectiveness bar in this country despite a cost-utility ratio that looks favourable by high-income standards, and what single change would most defensibly bring it within threshold?
A cochlear-implant programme has a cost-utility ratio of $13,000 per QALY. In which country is it MOST likely to be classified as NOT cost-effective under the WHO-CHOICE 1-3x GDP-per-capita rule?
Roughly what fraction of the global moderate-to-profound hearing-loss burden lies in low- and middle-income countries, and what share of candidates there are actually implanted, the gap that drives the chapter's equity argument?